THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, March 27, 2023
Pharma and biopharma laboratories have faced a key challenge in delivering faster turnaround times and results.
FREMONT, CA: The need for speedier turnaround times and outcomes in the pharmaceutical and biopharmaceutical industries has been a significant obstacle for many laboratories. Before the pandemic, 83 percent of respondents to a study of worldwide pharma lab chiefs by Agilent acknowledged that their procedures required optimization to keep up with demand. The pandemic exacerbated this strain, which expedited the digital transformation of numerous businesses, including the healthcare and life sciences sectors.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
There is, therefore, a growing expectation that drug research and development (R&D) should be accomplished more rapidly, but this places additional operational pressure on laboratories and other parties involved in bringing a drug product to market. Thankfully, lab automation and digitization advancements are leading to significant benefits throughout the pharmaceutical business. The discovery of novel drug candidates is illustrative of this phenomenon.
The collection of vast, produced datasets, which can now be processed with applications assisted by artificial intelligence (AI) and machine learning (ML) techniques to provide insights, is an additional crucial factor. This data can also be utilized to ensure compliance and generate the necessary documents in a highly regulated workplace. In addition, it offers advanced asset performance management approaches that guarantee scientists have access to the essential tools, as well as lab operational and budgetary optimization.
The two years of the pandemic pressured pharmaceutical corporations worldwide, including Hetero Group, which quickly realized the advantages of enhanced digitization. The company develops, manufactures, and markets high-quality chemicals and biologic medicines in various therapeutic fields. It is also one of the world's significant manufacturers of active pharmaceutical ingredients.
Hetero Group teams are responsible for analytical R&D, the validation and identification of molecules, and the quantification of impurities utilizing ICH Q3D guidance, which promotes a risk-based method for assessing the presence of elemental impurities in medicinal products. Hetero Group routinely works with big data sets generated by numerous lab facilities and procedures due to its diverse clientele.
Thankfully, the advantages of digitization apply to a vast array of applications, ranging from data analytics and forecasting to the automation of manufacturing and production processes.
The pandemic imparted a decade's worth of lessons in just two years. Digitalization of labs will be the pharmaceutical industry's future for various reasons, including speeding procedures, simplifying compliance, and boosting data security.
Digitalization in R&D facilitates simple compilation, visualization, and operational efficiencies. Additionally, it has assisted Hetero Group in enhancing its audit processes, delivering accurate data presentations, and generating comprehensive audit trails.
For instance, integrating a system with ECM has not only helped the pharmaceutical industry preserve data integrity and security but has also assured that data is readily accessible for quick reference and compilation with high precision. Server-based compliance consolidates everything under a single canopy and aids in establishing the crucial transparency of processes and accesses.
More in News